Topics

Aurinia's Voclosporin for Kidney Disease Caused by Lupus Hits Mark in Phase III

19:00 EST 4 Dec 2019 | BioSpace

“This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” said Neil Solomons, Aurinia’s chief medical officer.

Original Article: Aurinia's Voclosporin for Kidney Disease Caused by Lupus Hits Mark in Phase III

NEXT ARTICLE

More From BioPortfolio on "Aurinia's Voclosporin for Kidney Disease Caused by Lupus Hits Mark in Phase III"

Quick Search